Companion Diagnostics allows better custom treatment in cancer of ...

MDxHealth SA (BSE: MDXH), a business leader in Molecular Diagnostics in the field of personalized cancer treatment, announced today that its test MGMT (MDx predict brain) has demonstrated success in the treatment of brain cancer in phase international study III of customization. Data from Phase III (RTOG 0525) of TEMOZOLOMIDE study will be presented at the annual meeting of the American Society for Clinical Oncology (ASCO, Chicago, USA, 3-7 June) by the principal investigator Mark r. Gilbert, MD (University of Texas M. d. Anderson Cancer Center) on Sunday, June 5.

MGMT (O6-methylguanine-DNA methyltransferase) is an enzyme DNA repair key, produced by the MGMT gene. When the MGMT gene is methlyated, no MGMT is produced. Management more present in the tumor, the most active of DNA repair. This means that therapies that work by inducing DNA lesions are less likely to succeed.

About the study

0525 RTOG study was designed as a test of randomized phase III international comparing adjuvant standard temozolomide (TMZ) with a dose-dense (SD) calendar newly diagnosed glioblastoma (GBM) patients. Researchers are investigating whether a continuous dose of TEMOZOLOMIDE would be more effective than standard treatment. Test MGMT of MDxHealth was used to determine the status of methylation of MGMT gene and molecular classification of risks.

Test MGMT: PredictMDx for the brain

PredictMDx of the brain, produces custom treatment of more advanced MDxHealth is a test to predict the response of patient to agents, a class of alkylating chemotherapy drugs. The test to assess the State of methylation of the MGMT gene, which is essential to the promotion of the DNA repair. If the MGMT gene is methylated, cancer patients tend to respond better to the alkylating drug therapy. PredictMDx of the brain showed on thousands of patients to help identify patients with cancer who are likely to respond to the most commonly used class of drugs for cancer of the brain (alkylating agents). This patented DNA methylation gene test is attractive for new brain cancer drug developers since they can more easily target their new drugs for patients that do not generally meet the traditional alkylating agent drugs regime.

Source:
MDxHealth

Source: http://www.cancertherapyblog.com/cancer-news/companion-diagnostics-allows-better-custom-treatment-in-cancer-of-the-brain-of-methylation-of-the-mdxhealth-database/

may 21 meghan mccain adrianne curry john demjanjuk san antonio weather allegra mary tyler moore